For the Inventor, By the Inventor

Enter assignee name

Université De Paris

USPTO Granted Patents = 68

% Expired Patents = 2.9

EPO Patents = 36

Forward Citations = 48

Loading Chart...

Loading Chart...

271 inventors (with patents filed for the assignee):

Armand Bensussan (3 out of 20 patents)

Vincent Calvez (3 out of 7 patents)

Anne-Geneviève Marcelin (3 out of 6 patents)

4. Claire Wilhelm (2 out of 3 patents)

5. Nathalie Mignet (2 out of 5 patents)

6. Johanne Seguin (2 out of 3 patents)

7. Pierre Vidal (2 out of 5 patents)

8. Damien Ricard (2 out of 4 patents)

9. Laurent Oudre (2 out of 3 patents)

10. Nicolas Dupin (2 out of 4 patents)

11. Philippe Grange (2 out of 4 patents)

12. Antonino Nicoletti (2 out of 8 patents)

13. Giuseppina Caligiuri (2 out of 8 patents)

14. Roberto Mallone (2 out of 6 patents)

15. Georgia Afonso (2 out of 4 patents)

Core Competencies:

Cancer Treatment

Wound Healing

Immunomodulation

Tumor Recurrence

Antigenic Peptides

Microfluidic Devices

Super Resolution Imaging

Connective Tissue Regeneration

Extracellular Vesicles

Predicting Survival

Monoclonal Antibodies

Optical Lithography

68 patents: Sort by Forward Citations

1. 12674125 - Fluidic system for producing extracellular vesicles and associated method (2026-07-07),

2. 12673986 - ANTI-PROTEASE NEXIN-1 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF TO CONTROL BLEEDING (2026-07-07),

3. 12673087 - MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS (2026-07-07),

4. 12668812 - RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME (2026-06-30),

5. 12599662 - Methods and compositions for treating cancers (2026-04-14),

6. 12534550 - Amphipols (2026-01-27),

7. 12521392 - Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias (2026-01-13),

8. 12492230 - ANTIGENIC PEPTIDES DERIVING FROM SECRETOGRANIN V AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES (2025-12-09),

9. 12455284 - Double-stranded DNA molecule for the detecting and characterizing molecular interactions (2025-10-28),

10. 12390994 - System for controlled depositing of a fluid on a substrate (2025-08-19),

11. 12377066 - Treatment of diseases associated with biliary system destruction (2025-08-05),

12. 12336737 - Activation tool for a bone expansion apparatus (2025-06-24),

13. 12319745 - Antibodies having specificity for CD38 and uses thereof (2025-06-03),

14. 12242112 - Electro-optical conversion system (2025-03-04),

15. 12181694 - Electromagnetic cavity able to support Tamm modes (2024-12-31),

Company Overview

Université De Paris is a prominent academic institution located in Paris, France, specializing in advanced research and education in the field of cancer treatment. The university focuses on innovative approaches to combat cancer, including the development of immunomodulation therapies, antigenic peptides, and techniques for tumor recurrence management. Additionally, it explores cutting-edge technologies such as microfluidic devices and super-resolution imaging, contributing significantly to wound healing and connective tissue regeneration research.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

68 Patents

#106 in

#384 in

#10,888 in the World

Université De Paris

Forward Citations = 48

271 inventors:

Armand Bensussan (3 out of 20 patents)

Vincent Calvez (3 out of 7 patents)

Anne-Geneviève Marcelin (3 out of 6 patents)

4. Claire Wilhelm (2 out of 3 patents)

5. Nathalie Mignet (2 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Université De Paris. Retrieved from https://idiyas.com/company/universite-de-paris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…